Brokerages expect OptimizeRx Co. (NASDAQ:OPRX) to post $0.03 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for OptimizeRx’s earnings. The lowest EPS estimate is $0.01 and the highest is $0.06. OptimizeRx posted earnings of ($0.03) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 200%. The company is expected to announce its next earnings results on Wednesday, May 1st.
On average, analysts expect that OptimizeRx will report full-year earnings of $0.38 per share for the current financial year, with EPS estimates ranging from $0.29 to $0.43. For the next year, analysts forecast that the company will report earnings of $0.62 per share, with EPS estimates ranging from $0.48 to $0.75. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for OptimizeRx.
Several brokerages have issued reports on OPRX. Zacks Investment Research cut OptimizeRx from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. William Blair began coverage on OptimizeRx in a research report on Thursday, January 3rd. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $18.25.
In other news, major shareholder Awm Investment Company, Inc. sold 21,397 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.05, for a total value of $322,024.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Several institutional investors have recently bought and sold shares of OPRX. Park West Asset Management LLC boosted its position in shares of OptimizeRx by 63.3% in the 4th quarter. Park West Asset Management LLC now owns 967,448 shares of the company’s stock worth $10,613,000 after purchasing an additional 375,000 shares in the last quarter. Vanguard Group Inc acquired a new stake in shares of OptimizeRx in the 3rd quarter worth $5,204,000. 1492 Capital Management LLC acquired a new stake in shares of OptimizeRx in the 4th quarter worth $1,454,000. Avenir Corp boosted its position in shares of OptimizeRx by 74.2% in the 4th quarter. Avenir Corp now owns 117,400 shares of the company’s stock worth $1,288,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of OptimizeRx by 294.7% in the 4th quarter. Geode Capital Management LLC now owns 60,861 shares of the company’s stock worth $667,000 after purchasing an additional 45,440 shares in the last quarter. 45.94% of the stock is owned by hedge funds and other institutional investors.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.
Read More: What are gap-down stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.